178 related articles for article (PubMed ID: 33419852)
1. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
[TBL] [Abstract][Full Text] [Related]
3. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
4. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
[TBL] [Abstract][Full Text] [Related]
5. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma.
Sato Y; Nakano K; Wang X; Fukuda N; Urasaki T; Ohmoto A; Hayashi N; Yunokawa M; Ono M; Tomomatsu J; Saito M; Minami Y; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944888
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S; Shimoi T; Satomi-Tsushita N; Yazaki S; Okuya T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Yonemori K
BMC Cancer; 2022 Jan; 22(1):64. PubMed ID: 35027011
[TBL] [Abstract][Full Text] [Related]
7. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
[TBL] [Abstract][Full Text] [Related]
8. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
[TBL] [Abstract][Full Text] [Related]
9. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer.
Myojin M; Horimoto Y; Ito M; Kitano S; Ishizuka Y; Sasaki R; Uomori T; Himuro T; Murakami F; Nakai K; Iijima K; Saito M
Breast Cancer; 2020 Jul; 27(4):732-738. PubMed ID: 32108306
[TBL] [Abstract][Full Text] [Related]
11. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin.
Ishihara S; Ogura K; Maejima A; Shimoi T; Sudo K; Kojima Y; Fukushima S; Osaki S; Kobayashi E; Iwata S; Matsui Y; Yonemori K; Kawai A
Jpn J Clin Oncol; 2023 Jun; 53(6):494-500. PubMed ID: 36989466
[TBL] [Abstract][Full Text] [Related]
13. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
14. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
[TBL] [Abstract][Full Text] [Related]
15. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
16. Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin.
Kobayashi H; Okuma T; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Goto T; Tanaka S
J Orthop Sci; 2022 Jan; 27(1):222-228. PubMed ID: 33384219
[TBL] [Abstract][Full Text] [Related]
17. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
Watanabe J; Saito M; Horimoto Y; Nakamoto S
Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
[TBL] [Abstract][Full Text] [Related]
18. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
[TBL] [Abstract][Full Text] [Related]
19. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma.
Chan JY; Zhang Z; Chew W; Tan GF; Lim CL; Zhou L; Goh WL; Poon E; Somasundaram N; Selvarajan S; Sittampalam K; Chin F; Teh J; Tan MH; Soo KC; Teo M; Farid M; Quek R
Sci Rep; 2018 Aug; 8(1):11959. PubMed ID: 30097600
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
